Much-Publicized Report on Financial Returns on Cancer Treatments Contains Significant Flaws and Biases, Finds New Center for Medical Economics and Innovation Brief
New PRI Brief Finds WHO Report Overstates Returns by 350 Percent or More
SAN FRANCISCO, June 12, 2019 /PRNewswire/ -- The World Health Organization (WHO) is advocating that the price of cancer treatments are excessive, but its report that justifies this conclusion contains significant biases that drastically over-estimates the revenues multiple over research and development (R&D) costs, according to a new issue brief released today by the Center for Medical Economics and Innovation at the non-partisan Pacific Research Institute.
"Cancer medications have revolutionized treatment, and it's unfortunate if the WHO's flawed analysis jeopardizes patients' access to these life-saving medicines," says author Dr. Wayne Winegarden. "The misinformation perpetuated by the study inappropriately supports the imposition of price controls and more government regulation, which would actually threaten innovation and make cutting-edge cancer treatments less available to patients."
In "A Review of the WHO Technical Report," Winegarden analyzes an oft-cited study by the World Health Organization ("Pricing of Cancer Medications and its Impacts"), which concludes that life sciences companies receive an average return of $14.50 for every dollar invested in R&D.
Winegarden notes that the report is flawed in two key areas. First, it did not include 37 percent of the FDA-approved cancer medications in its study. As a result, the WHO study significantly underestimated R&D costs and overstated the revenue multiple of sales revenues to R&D expenditures.
Additionally, the WHO study does not account for the time value of money. By taking into account these errors, Winegarden found the multiple of sales revenue to R&D could be inflated by 63.4 percent for the 99 drugs studied, and by 76.7 percent for all 156 drugs approved by the FDA over this time period.
- Accounting for the first bias – incorporating all 156 approved cancer medications -would reduce the revenue multiple to $9.20 in revenue per dollar invested in R&D.
- Accounting for the time value of money could reduce the figure to $3.16 per dollar invested.
"By applying basic economic principles, our brief concludes that the estimates of returns on R&D for cancer treatments could be inflated by as much as 350 percent or more in the WHO study," Winegarden said. "When it comes to matters of life and death, it's important that studies like these take an honest look at the issue, one that doesn't pave the way for troubling policy changes that would worsen the problem."
Dr. Wayne Winegarden is the director of the Center for Medical Economics and Innovation at the Pacific Research Institute, and a PRI Senior Fellow in Business and Economics. He is also the Principal of Capitol Economic Advisors.
The Center for Medical Economics and Innovation at the Pacific Research Institute (www.medecon.org) aims to educate policymakers, regulators, healthcare professionals, the media, and the public on the critical role that new technologies play in improving health and accelerating economic growth.
PRI (www.pacificresearch.org) champions freedom, opportunity, and personal responsibility by advancing free-market policy ideas. Follow PRI on Facebook, Twitter, and LinkedIn.
MEDIA CONTACT
Madeline Auerbach
202-471-4228 ext. 101
[email protected]
SOURCE Pacific Research Institute
Share this article